{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04881240",
            "orgStudyIdInfo": {
                "id": "MEMCAR19"
            },
            "organization": {
                "fullName": "St. Jude Children's Research Hospital",
                "class": "OTHER"
            },
            "briefTitle": "Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia",
            "officialTitle": "A Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients \u2264 21 Years of Age With Relapsed or Refractory CD19-Positive Leukemia",
            "therapeuticArea": [
                "Pediatrics",
                "Oncology and Hematology"
            ],
            "study": "study-of-directed-allogeneic-memory-t-cell-therapy-for-relapsed-refractory-leukemia"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2024-02-14",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-04-27",
            "studyFirstSubmitQcDate": "2021-05-05",
            "studyFirstPostDateStruct": {
                "date": "2021-05-11",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-05",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-06",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "St. Jude Children's Research Hospital",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase I clinical study evaluating the safety and maximum tolerated dose of a novel CAR T-cell product: allogeneic memory (CD45RA- negative) T-cells expressing a CD19-specific CAR 41BBz (CD19-CAR.CD45RA- negative T-cells) for the treatment of patients \u2264 21 years old with relapsed and/ or refractory CD19-positive leukemia.\n\nPrimary Objective\n\nTo determine the maximum tolerated dose (MTD) and characterize the safety profile and dose-limiting toxicities (DLTs) of treatment with allogeneic CD19-CAR.CD45RA-negative T-cells in pediatric, adolescent and young adult patients \u2264 21 years of age, with relapsed and/or refractory CD19-positive leukemia.\n\nSecondary Objectives\n\n* To evaluate the anti-leukemic activity of allogeneic CD19-CAR.CD45RA-negative T-cells.\n* To determine rates and severity of graft-versus-host-disease (GVHD) after treatment with allogeneic CD19-CAR.CD45RA-negative T-cells.\n\nExploratory Objectives\n\n* To study the expansion, persistence and phenotype of allogeneic CD19-CAR.CD45RA-negative T-cells.\n* To characterize the cytokine profile in the peripheral blood and CSF after treatment with allogeneic CD19-CAR.CD45RA-negative T-cells.\n* To assess whether allogeneic CD19-CAR.CD45RA-negative T-cells acquire functional versus exhaustion-associated epigenetic programs.\n* To determine immune reconstitution post treatment, and the clonal structure and endogenous repertoire of allogeneic CD19-CAR.CD45RA-negative T-cells and relate inferred specificity to CAR response profiles.\n* To characterize incidence and mechanisms of relapse post-therapy with allogeneic CD19-CAR.CD45RA-negative T-cells.",
            "detailedDescription": "This is a Phase I dose escalation study using a 3+3 study design. Two groups of patients will be evaluated in this study: group A - patients have received a prior stem cell transplant from their CAR T-cell donor; group B - patients have not received a prior stem cell transplant from their CAR T-cell donor. There will be up to 30 participants per group and a donor/ family member for each patient.\n\n."
        },
        "conditionsModule": {
            "conditions": [
                "Acute Lymphoblastic Leukemia, in Relapse",
                "Acute Lymphoblastic Leukemia, Refractory",
                "Pediatric ALL"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 60,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Group A",
                    "type": "EXPERIMENTAL",
                    "description": "Participants in group A have received a prior stem cell transplant from their CAR T-cell donor.",
                    "interventionNames": [
                        "Biological: CD19-CAR(Mem) T-cells",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine",
                        "Drug: Mesna",
                        "Device: CliniMACS",
                        "Procedure: Leukapheresis"
                    ]
                },
                {
                    "label": "Group B",
                    "type": "EXPERIMENTAL",
                    "description": "Participants in group B have not received a prior stem cell transplant from their CAR T-cell donor.",
                    "interventionNames": [
                        "Biological: CD19-CAR(Mem) T-cells",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine",
                        "Drug: Mesna",
                        "Device: CliniMACS",
                        "Procedure: Leukapheresis"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "CD19-CAR(Mem) T-cells",
                    "description": "Allogeneic CD19-CAR.CD45RA-negative T-cells Intravenous infusion",
                    "armGroupLabels": [
                        "Group A",
                        "Group B"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cyclophosphamide",
                    "description": "Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.",
                    "armGroupLabels": [
                        "Group A",
                        "Group B"
                    ],
                    "otherNames": [
                        "Cytoxan"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Fludarabine",
                    "description": "Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis.",
                    "armGroupLabels": [
                        "Group A",
                        "Group B"
                    ],
                    "otherNames": [
                        "Fludara"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Mesna",
                    "description": "Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide.",
                    "armGroupLabels": [
                        "Group A",
                        "Group B"
                    ],
                    "otherNames": [
                        "Mesnex"
                    ]
                },
                {
                    "type": "DEVICE",
                    "name": "CliniMACS",
                    "description": "A CliniMACS device is used to select donor T-cells for manufacturing of the memory CAR T-cell product.",
                    "armGroupLabels": [
                        "Group A",
                        "Group B"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Leukapheresis",
                    "description": "Leukapheresis is performed to collect the T cells that are needed to generate the CD19-CAR.CD45RA-negative T-cells product for the clinic study.",
                    "armGroupLabels": [
                        "Group A",
                        "Group B"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Maximum tolerated dose of allogeneic, CD19-CAR.CD45RA-negative cells",
                    "description": "This phase I study includes dose escalation/de-escalation based on dose limiting toxicity (DLT) assessment to determine the maximum tolerated dose (MTD) of allogeneic, CD19-CAR.CD45RA-negative cells.",
                    "timeFrame": "4 weeks after CAR T-cell infusion"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria Eligibility Criteria for Donors: Apheresis and Manufacturing\n\n* Age \u2265 18 years old\n* At least single haplotype matched (\u2265 3/6) family member\n* HIV negative\n* For females of child bearing age: Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment AND Not lactating with intent to breastfeed\n* Completed the process of donor eligibility determination as outlined in 21 CFR 1271 and agency guidance\n\nFor Cohort A only, identified recipient with relapsed and/or refractory CD19-positive leukemia\n\nFor Cohort B only, iIdentified recipient with relapsed and/or refractory CD19-positive leukemia who is not suitable to receive autologous CD19-CAR T-cell therapy as defined by the following:\n\n* Relapsed and/or refractory disease despite prior treatment with autologous CD19- CAR T-cell therapy\n* History of prior autologous leukapheresis failure\n* History of prior autologous CAR T-cell manufacturing failure\n* Unable to undergo autologous leukapheresis in the opinion of the study PI(s): examples may include - patient small size/low weight, inadequate T-cell counts, rapidly progressive leukemia, clinical status not amenable to apheresis\n\nEligibility Criteria for Patients: Treatment\n\n* Age \u2264 21 years old\n* Relapsed and/or refractory CD19-positive leukemia\\*:\n\n  * Refractory disease (defined as any of the following):\n\n    * Primary refractory disease despite at least 2 cycles of an intensive chemotherapy regimen designed to induce remission\n    * Refractory disease despite salvage therapy\n  * Relapsed disease (defined as any of the following):\n\n    * 2nd or greater relapse\n    * Any relapse after allogeneic hematopoietic cell transplantation (HCT)\n    * 1st relapse if patient requires an allogeneic HCT as part of standard of care relapse therapy, but is found to be ineligible and/or unsuitable for HCT\n\nCD19-positivity confirmed within 2 months and after receipt of any CD19-directed therapy\n\n* Patient cohorts:\n\n  * Cohort A: patient has previously received a HCT from the selected CAR T-cell donor\n  * Cohort B - patient has NOT previously received a HCT from the selected CAR T-cell donor.\n* For Cohort B only, not suitable to receive autologous CD19-CAR T-cell therapy as defined above in Criteria: Eligibility Criteria for Donors: Apheresis and Manufacturing\n* Detectable medullary CD19-positive leukemia\n* Estimated life expectancy of \u2265 8 weeks\n* Karnofsky or Lansky performance score \u2265 50\n* No CNS-3 disease or any level of detectable leukemia in CNS with associated neurologic symptoms\n* If history of allogeneic HCT (regardless of donor type), prior to planned CAR T-cell infusion, must meet the following criteria:\n\n  * \u2265 3 months from HCT\n  * have recovered from prior HCT therapy\n  * have no evidence of active GVHD within prior 2 months\n  * have not received a donor lymphocyte infusion (DLI) within the 28 days prior to planned CAR T-cell infusion\n* Adequate cardiac function: left ventricular ejection fraction \u2265 40% or shortening fraction \u2265 25% (function may be supported by pharmacologic therapy)\n* EKG without evidence of clinically significant arrhythmia\n* Adequate renal function: creatinine clearance or radioisotope GFR 50 ml/min/1.73m2 (GFR 40 ml/min/1.73m2 if \\< 2 years of age)\n* Adequate pulmonary function: forced vital capacity (FVC) \u2265 50% of predicted value; or pulse oximetry \u2265 92% on room air if patient is unable to perform pulmonary function testing\n* Total bilirubin \u2264 3 times the upper limit of normal for age, except in subjects with Gilbert's syndrome\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \u2264 5 times the upper limit of normal for age\n* No history of HIV infection\n* No evidence of severe, uncontrolled bacterial, viral or fungal infection\n* Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy\n* For females of child bearing age:\n\n  * Not pregnant with negative serum or urine pregnancy test \u2264 7 days prior to enrollment AND Not lactating with intent to breastfeed\n* If sexually active, agreement to use birth control until 6 months after CAR T-cell infusion\n* No history of hypersensitivity reactions to murine protein-containing products\n* Not receiving systemic steroids therapy exceeding the equivalent of 0.5 mg/kg/day of methylprednisolone \u2264 7 days prior to CAR T-cell infusion\n* Not receiving systemic therapy \u2264 14 days prior to CAR T-cell infusion, which will interfere with the activity of the CAR T-cell product in vivo (in the opinion of the study PI(s))\n* Not receiving intrathecal chemotherapy \u2264 7 days prior to CAR T-cell infusion\n\nExclusion Criteria:\n\nNA",
            "healthyVolunteers": false,
            "sex": "ALL",
            "maximumAge": "21 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Aimee C. Talleur, MD",
                    "role": "CONTACT",
                    "phone": "866-278-5833",
                    "email": "referralinfo@stjude.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Aimee C. Talleur, MD",
                    "affiliation": "St. Jude Children's Research Hospital",
                    "role": "PRINCIPAL_INVESTIGATOR"
                },
                {
                    "name": "Stephen Gottschalk, MD",
                    "affiliation": "St. Jude Children's Research Hospital",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "St. Jude Children's Research Hospital",
                    "status": "RECRUITING",
                    "city": "Memphis",
                    "state": "Tennessee",
                    "zip": "38105",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Aimee C. Talleur, MD",
                            "role": "CONTACT",
                            "phone": "866-278-5833",
                            "email": "referralinfo@stjude.org"
                        },
                        {
                            "name": "Aimee C. Talleur, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Stephen Gottschalk, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.14953,
                        "lon": -90.04898
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "St. Jude Children's Research Hospital",
                    "url": "http://www.stjude.org"
                },
                {
                    "label": "Clinical Trials Open at St. Jude",
                    "url": "http://www.stjude.org/protocols"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007938",
                    "term": "Leukemia"
                },
                {
                    "id": "D000054198",
                    "term": "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
                },
                {
                    "id": "D000007945",
                    "term": "Leukemia, Lymphoid"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M27585",
                    "name": "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
                    "asFound": "Acute Lymphoblastic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "asFound": "Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10951",
                    "name": "Leukemia, Lymphoid",
                    "asFound": "Lymphoblastic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T175",
                    "name": "Acute Lymphoblastic Leukemia",
                    "asFound": "Acute Lymphoblastic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3533",
                    "name": "Lymphoblastic Lymphoma",
                    "asFound": "Acute Lymphoblastic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1134",
                    "name": "Childhood Acute Lymphoblastic Leukemia",
                    "relevance": "LOW"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "C000024352",
                    "term": "Fludarabine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10117",
                    "name": "Ifosfamide",
                    "relevance": "LOW"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "asFound": "Rate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M230811",
                    "name": "Isophosphamide mustard",
                    "relevance": "LOW"
                },
                {
                    "id": "M11449",
                    "name": "Mechlorethamine",
                    "relevance": "LOW"
                },
                {
                    "id": "M12525",
                    "name": "Nitrogen Mustard Compounds",
                    "relevance": "LOW"
                },
                {
                    "id": "M17811",
                    "name": "Mesna",
                    "relevance": "LOW"
                },
                {
                    "id": "M344727",
                    "name": "2'-deoxyadenosine",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}